<DOC>
	<DOCNO>NCT01572987</DOCNO>
	<brief_summary>This clinical trial evaluate patient population Barrett 's esophagus ( BE ) contain high grade dysplasia intramucosal cancer compare effect endoscopically-guided radiofrequency ablation system ( RFA ) endoscopically-guided stepwise endoscopic mucosal resection ( S-EMR ) .</brief_summary>
	<brief_title>Endoscopic Resection Ablation Patients With Dysplasia Cancer Requiring Treatment Barrett 's Esophagus</brief_title>
	<detailed_description>This multi-center prospective , randomize control trial conduct 4 center . The patient high grade dysplasia ( HGD ) and/or esophageal cancer ( EC ) meet study criterion enrol , undergo baseline diagnostic EMR randomize 1:1 ratio undergo treatment either S-EMR radiofrequency ablation ( RFA ) . The initial staging EMR extend 50 % esophageal circumference 2 cm longitudinal extent . Patients S-EMR group undergo step-wise eradication BE segment use Duette multi-band mucosectomy kit ( Cook Medical , FDA approve ) whereas RFA group undergo BE ablation use endoscopically-guided HALO radiofrequency ablation system ( Barrx Medical , FDA approve ) . Both treatment group undergo respective treatment session every 2 month either Barrett 's esophagus see maximum 4 treatment session . Once visible Barrett 's esophagus , patient undergo surveillance biopsy ( random 4 quadrant biopsy every 1 cm neo-squamous mucosa random biopsy cardia ) evaluate complete eradication Barrett 's esophagus . Regardless whether visible Barrett 's esophagus , patient undergo repeat endoscopy every 2 month 1 year enrollment . If visible Barrett 's esophagus see endoscopy , surveillance biopsy evaluate dysplasia take . Regardless whether visible Barrett 's esophagus , patient undergo surveillance biopsy 12 month enrollment . The objective study compare proportion patient complete eradication Barrett 's esophagus use S-EMR versus RFA 12 month .</detailed_description>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Subjects shall screen accord follow inclusion criterion . An answer `` '' inclusion criterion disqualifies subject participate study . Patients age : &gt; 18 year Subject document diagnosis Barrett 's esophagus , maximum endoscopic length C2M5 ( i.e . 2cm circumferential extent 5cm tongue ) contain HGD/EC follow : HGD EC document biopsy within previous 6 month enrollment Histology slide review central pathology service ERADICATE Trial confirm HGD/EC . Endoscopically visible lesion/area/pattern patient HGD/EC either high definition white light endoscopy , narrow band imaging , confocal laser endomicroscopy , another enhance image tool . Ability take oral proton pump inhibitor For female subject childbearing potential , negative urine pregnancy test within 2 week enrollment subsequent endoscopy encounter Subject eligible treatment followup endoscopy biopsy require investigational plan Ability discontinue aspirin/NSAIDs/Clopidogrel 7 day ablation procedure Ability provide write , informed consent understand responsibility trial participation NOTE : At Kansas City Veterans Hospital , participant must eligible care VA order enrol . Other site list able enroll nonveterans . Subjects shall screen accord follow exclusion criterion . An answer `` yes '' exclusion criterion disqualifies subject participate study . Extent BE &gt; C2M5 The subject pregnant planning pregnancy study period ( 12 month treatment ) Esophageal stricture prevent passage endoscope catheter Active erosive esophagitis History malignancy esophagus , esophageal varix coagulopathy Prior radiation therapy esophagus , except head neck region radiation therapy . Any previous ablation therapy within esophagus ( photodynamic therapy , multipolar electrocoagulation , argon plasma coagulation , laser treatment , ) Any previous EMR esophagus Any previous esophageal surgery , include fundoplication Evidence esophageal varix treatment endoscopy Subject lifeexpectancy less two year due underlie medical condition Subject know history unresolved drug alcohol dependency would limit ability comprehend follow instruction relate informed consent , posttreatment instruction , followup guideline Subject implantable pacing device ( example : Implantable cardiac defibrillator , neurostimulator , cardiac pacemaker ) receive clearance enrollment study specialist responsible pacing device The subject currently enrol investigational drug device trial clinically interfere ERADICATE trial . Subject suffers psychiatric illness deem investigator inability comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Barrett 's Esophagus</keyword>
	<keyword>Esophageal neoplasm</keyword>
	<keyword>Radiofrequency ablation</keyword>
	<keyword>Endoscopic mucosal resection</keyword>
</DOC>